1-ethylphenoxathiin

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 1-ethylphenoxathiin
• 英文别名: 1-Ethyl-phenoxathiine；1-ethylphenoxathiine
• 化学式: C₁₄H₁₂OS
• 分子量: 228.315
• InChiKey: PJLJUHYRWZCAJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-乙基吩恶噻10,10-二氧化物 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 5.0h， 生成 1-ethylphenoxathiin
  参考文献：
  名称：

  Selective Inhibitors of Monoamine Oxidase (MAO). 5. 1-Substituted Phenoxathiin Inhibitors Containing No Nitrogen That Inhibit MAO A by Binding It to a Hydrophobic Site

  摘要：

  It is believed that a monoamine oxidase (MAO) inhibitor specific for MAO A, which is reversibly bound to this enzyme and displaceable:by tyramine, will be an antidepressant which will not cause a rise in blood pressure when tyramine-containing foods are ingested. Some linear tricyclic compounds with a larger and a smaller group forming the central ring and with a lipophilic group ortho to the larger group (here mostly the SO2 function of phenoxathiin 10, -10-dioxide) are reported to have the sought properties. Potency appears to require short length and relatively small cross section for the substituent. The 1-ethyl (13), 1-vinyl (22), 1-trifluoromethyl (27), and 1-iodo (76) phenoxathiin dioxides had the best profiles. Structure-activity relationships, syntheses, and a possible rationale for the selectivity of these compounds and related tricyclics are given. Compound 13 was selected for further development. A summary of pharmacological data for 13 is given.

  DOI：

  10.1021/jm970862j

文献信息

• Verfahren zur Herstellung von 2-Chlor-4-nitro-alkylbenzol
  申请人：BAYER AG

  公开号：EP0399293A1

  公开（公告）日：1990-11-28

  Bei der Herstellung von 2-Chlor-4-nitro-alkylbenzol durch Umsetzung von 4-Nitro-alkylbenzol mit elementarem Chlor oder Chlor abgebenden Verbindungen in Gegenwart eines Friedel-Crafts-Katalysators in flüssiger Phase werden besonders hohe Selektivitäten bezüglich der aus­schließlich in 2-Position chlorierten Zielverbindungen erreicht, wenn als Co-Katalysator ein dibenzokonden­sierter Schwefelheterocyclus der Formel mit den in der Beschreibung angegebenen Bedeutungen für R¹ bis R⁸, X und n eingesetzt wird.

  在液相中，在弗里德尔-卡夫斯催化剂存在下，通过 4-硝基烷基苯与元素氯或供氯 化合物反应制备 2-氯-4-硝基烷基苯时，如果使用式如下的二苯并缩硫杂环作为助催 化剂，则对完全在 2 位氯化的目标化合物具有特别高的选择性 式中 R¹至 R⁸、X 和 n 的含义在描述中给出。
• JPH03145486A
  申请人：——

  公开号：JPH03145486A

  公开（公告）日：1991-06-20
• Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases
  申请人：Mann David M.

  公开号：US20110091421A1

  公开（公告）日：2011-04-21

  The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed.
• Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Disease
  申请人：Vascular Biosciences

  公开号：US20170145505A1

  公开（公告）日：2017-05-25

  Multiple treatment regimens for vascular-related diseases and disorders. Methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods for diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorders involving targeting microRNAs.
• US5420156A
  申请人：——

  公开号：US5420156A

  公开（公告）日：1995-05-30